These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 20798865)

  • 1. Molecular and therapeutic potential and toxicity of valproic acid.
    Chateauvieux S; Morceau F; Dicato M; Diederich M
    J Biomed Biotechnol; 2010; 2010():. PubMed ID: 20798865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hidden pharmacological activities of valproic acid: A new insight.
    Singh D; Gupta S; Verma I; Morsy MA; Nair AB; Ahmed AF
    Biomed Pharmacother; 2021 Oct; 142():112021. PubMed ID: 34463268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproic acid selectively suppresses the formation of inhibitory synapses in cultured cortical neurons.
    Kumamaru E; Egashira Y; Takenaka R; Takamori S
    Neurosci Lett; 2014 May; 569():142-7. PubMed ID: 24708928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid.
    Qiao L; Schaack J; Shao J
    Endocrinology; 2006 Feb; 147(2):865-74. PubMed ID: 16282359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection.
    Monti B; Polazzi E; Contestabile A
    Curr Mol Pharmacol; 2009 Jan; 2(1):95-109. PubMed ID: 20021450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental studies and controlled clinical testing of valproate and vigabatrin.
    Gram L
    Acta Neurol Scand; 1988 Oct; 78(4):241-70. PubMed ID: 3146860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-function studies for the panacea, valproic acid.
    Terbach N; Williams RS
    Biochem Soc Trans; 2009 Oct; 37(Pt 5):1126-32. PubMed ID: 19754465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition.
    Jeong MR; Hashimoto R; Senatorov VV; Fujimaki K; Ren M; Lee MS; Chuang DM
    FEBS Lett; 2003 May; 542(1-3):74-8. PubMed ID: 12729901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic Acid: second generation.
    Bialer M; Yagen B
    Neurotherapeutics; 2007 Jan; 4(1):130-7. PubMed ID: 17199028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors.
    Dedoni S; Marras L; Olianas MC; Ingianni A; Onali P
    J Pharmacol Exp Ther; 2019 Sep; 370(3):490-503. PubMed ID: 31308194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity.
    Leng Y; Chuang DM
    J Neurosci; 2006 Jul; 26(28):7502-12. PubMed ID: 16837598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid enhances neuronal differentiation of sympathoadrenal progenitor cells.
    Vukićević V; Qin N; Balyura M; Eisenhofer G; Wong ML; Licinio J; Bornstein SR; Ehrhart-Bornstein M
    Mol Psychiatry; 2015 Aug; 20(8):941-50. PubMed ID: 25707399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproic acid inhibits neurosphere formation by adult subventricular cells by a lithium-sensitive mechanism.
    Zhou Q; Dalgard CL; Wynder C; Doughty ML
    Neurosci Lett; 2011 Aug; 500(3):202-6. PubMed ID: 21741439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic Acid Limits Pancreatic Recovery after Pancreatitis by Inhibiting Histone Deacetylases and Preventing Acinar Redifferentiation Programs.
    Eisses JF; Criscimanna A; Dionise ZR; Orabi AI; Javed TA; Sarwar S; Jin S; Zhou L; Singh S; Poddar M; Davis AW; Tosun AB; Ozolek JA; Lowe ME; Monga SP; Rohde GK; Esni F; Husain SZ
    Am J Pathol; 2015 Dec; 185(12):3304-15. PubMed ID: 26476347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproic acid exposure leads to upregulation and increased promoter histone acetylation of sepiapterin reductase in a serotonergic cell line.
    Balasubramanian D; Deng AX; Doudney K; Hampton MB; Kennedy MA
    Neuropharmacology; 2015 Dec; 99():79-88. PubMed ID: 26151765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valproic acid phase shifts the rhythmic expression of Period2::Luciferase.
    Johansson AS; Brask J; Owe-Larsson B; Hetta J; Lundkvist GB
    J Biol Rhythms; 2011 Dec; 26(6):541-51. PubMed ID: 22215612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of human gamma/delta T-cell activation and phenotype by histone deacetylase inhibitors.
    Bhat J; Oberg HH; Kabelitz D
    Cell Immunol; 2015 Jul; 296(1):50-6. PubMed ID: 25708484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
    Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
    J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproic acid in the complex therapy of malignant tumors.
    Hrebackova J; Hrabeta J; Eckschlager T
    Curr Drug Targets; 2010 Mar; 11(3):361-79. PubMed ID: 20214599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of valproic acid-initiated homologous recombination.
    Sha K; Winn LM
    Birth Defects Res B Dev Reprod Toxicol; 2010 Apr; 89(2):124-32. PubMed ID: 20437471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.